Share:

United States Allergy Treatment Market Size, Share, Growth, Trends, Industry Analysis & Forecast 2026–2034
United States Allergy Treatment Market Overview
The United States Allergy Treatment Market is experiencing steady growth, driven by the increasing prevalence of allergic diseases, rising healthcare awareness, advancements in pharmaceutical treatments, and growing adoption of immunotherapy. According to Renub Research, the United States allergy treatment market is expected to increase from US$ 6.33 billion in 2025 to US$ 10.61 billion by 2034, registering a compound annual growth rate (CAGR) of 5.91% during 2026–2034.
Allergy treatment includes a range of medical therapies designed to prevent, manage, and relieve allergic reactions caused by substances such as pollen, dust mites, pet dander, certain foods, insect venom, and medications. Common treatment options include antihistamines, decongestants, corticosteroids, leukotriene modifiers, and advanced biologic therapies. Immunotherapy, administered through allergy shots or sublingual tablets, is also gaining importance as a long-term treatment approach.
The growing prevalence of allergic rhinitis, asthma, food allergies, allergic conjunctivitis, and atopic dermatitis is increasing demand for effective treatment solutions across the United States. Furthermore, pharmaceutical innovation, improved diagnostic capabilities, and greater patient awareness are supporting market expansion.
Key Growth Drivers of the United States Allergy Treatment Market
1. Increasing Prevalence of Allergic Diseases
The rising incidence of allergic conditions represents one of the most significant growth drivers in the United States allergy treatment market. Allergic rhinitis, asthma, food allergies, eye allergies, and atopic dermatitis affect millions of Americans across different age groups.
Environmental pollution, climate change, urbanization, lifestyle changes, and prolonged exposure to allergens are contributing to increasing allergy diagnosis rates. Patients experiencing recurring or chronic symptoms are increasingly seeking prescription medications, over-the-counter treatments, and long-term immunotherapy solutions.
According to the statistics included in the Renub Research report, in 2021, approximately 27.2% of children and 31.8% of adults in the United States reported having seasonal allergies, eczema, or food allergies. This represents more than 100 million people and highlights the substantial demand for allergy management solutions.
Increasing awareness of early diagnosis and preventive treatment is also encouraging patients to seek medical attention before allergic conditions become more severe. Consequently, the growing patient population is supporting consistent demand for allergy medications and specialized therapies.
2. Pharmaceutical Innovation and Advanced Biologic Therapies
Technological advancements and pharmaceutical research are transforming the United States allergy treatment industry. Biologic medications targeting specific immune pathways are creating new treatment opportunities for patients suffering from severe or treatment-resistant allergic conditions.
Unlike conventional medications that primarily manage symptoms, certain biologic therapies target specific mechanisms involved in allergic reactions. These treatments are expanding options for patients who do not achieve sufficient relief through traditional medications.
Improvements in immunotherapy are also supporting market development. Traditional allergy injections are increasingly complemented by sublingual tablets and other convenient formulations.
A significant development occurred in February 2024, when the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for certain adults and children aged one year or older with immunoglobulin E-mediated food allergies. The treatment is intended to reduce allergic reactions, including the risk of anaphylaxis, following accidental exposure to one or more food allergens. Patients must continue avoiding foods to which they are allergic, as the treatment is not an emergency solution for anaphylaxis.
These developments demonstrate the growing importance of pharmaceutical innovation in expanding treatment possibilities and supporting the long-term growth of the market.
3. Growing Awareness and Early Allergy Diagnosis
Increasing awareness regarding allergic diseases and their potential long-term impact is encouraging patients to pursue early diagnosis and consistent treatment.
Public health campaigns, improved access to allergy specialists, diagnostic testing, and digital healthcare information are helping individuals identify allergy symptoms more effectively. Patients are increasingly recognizing that untreated allergies can affect sleep quality, productivity, respiratory health, and overall quality of life.
Healthcare providers and insurers are also emphasizing preventive healthcare to reduce the long-term costs associated with unmanaged allergic conditions.
In September 2025, Food Allergy Research & Education (FARE) announced the release of its RISE public service announcement. The campaign uses dance as a metaphor to encourage people living with food allergies to understand available treatment options, connect with communities, and take appropriate action.
Such awareness initiatives are supporting patient education and encouraging greater engagement with allergy management services.
Challenges in the United States Allergy Treatment Market
1. High Cost of Advanced Allergy Treatments
Share:
More in Business
View category
How to Choose a CPaaS Platform That Supports an RCS Messaging Platform
Learn how to select a reliable CPaaS platform with native RCS messaging support, smart SMS fallback, and scalable APIs to boost customer engagement.
READ ARTICLE

